Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.

International journal of particle therapy·2026
Same author

A Systematic Study on Local Failure Events Post Chemoradiation Therapy for Cervical Cancer: Understanding the Impact of Baseline Lateral Anatomic Compartment Involvement.

International journal of radiation oncology, biology, physics·2025
Same author

Pattern of recurrence with 1.0 cm CTV in brain glioblastoma treated with radiotherapy.

Journal of neuro-oncology·2025
Same author

Association Between Brain Substructure Dose and Scholastic Performance in Pediatric Brain Tumor Survivors Who Received Radiation Therapy.

International journal of radiation oncology, biology, physics·2025
Same author

Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies.

International journal of particle therapy·2025

Related Experiment Video

Updated: May 18, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Radiotherapy for pleomorphic adenoma.

Audrey S Wallace1, Christopher G Morris, Jessica M Kirwan

  • 1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610-0385, USA.

American Journal of Otolaryngology
|September 11, 2012
PubMed
Summary
This summary is machine-generated.

Radiotherapy (RT) effectively controls pleomorphic adenoma, especially subclinical disease post-surgery. This study confirms RT

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: May 18, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

  • Oncology
  • Radiation Oncology
  • Head and Neck Surgery

Background:

  • Pleomorphic adenoma is the most common salivary gland neoplasm.
  • Recurrence after surgery can occur, particularly with subclinical disease.
  • Radiotherapy (RT) is an option for managing pleomorphic adenoma, especially in high-risk cases.

Purpose of the Study:

  • To evaluate the efficacy of radiotherapy (RT) in treating pleomorphic adenoma.
  • To update experience with RT for pleomorphic adenoma management.
  • To assess long-term outcomes and complications of RT for pleomorphic adenoma.

Main Methods:

  • Retrospective analysis of 25 patients with pleomorphic adenoma treated with RT.
  • Patients received RT alone (2) or combined with surgery (23).
  • Follow-up ranged from 1.8 to 34.9 years (median 10.5 years).

Main Results:

  • Overall local control was achieved in 72% of patients (18/25).
  • Local control rates were 76% for subclinical disease and 56% for gross disease.
  • Common complications included dental caries and transient facial nerve deficits; no severe RT complications were reported.

Conclusions:

  • Radiotherapy is effective in controlling subclinical pleomorphic adenoma in high-risk patients post-surgery.
  • RT offers a viable treatment option for pleomorphic adenoma, with acceptable toxicity.
  • Long-term follow-up indicates durable local control for many patients treated with RT.